To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

Phase 1 Completed 20 enrolled Sandoz

RandomizedCrossoverOpen-labelTreatment

Summary

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Timeline

Start: 2004-03
Primary completion: 2004-03
Completion: 2004-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Levetiracetam	Other / unclassified	750 mg	—

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

Summary

Timeline

Drugs

Indications